NCT03342144 Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting
| NCT ID | NCT03342144 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AbbVie |
| Condition | Chronic Lymphocytic Leukemia (CLL) |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2017-12-04 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2017-12-04 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
An observational study to assess the effectiveness, health economic-relevant costs and participant reported outcomes in participants with Chronic lymphocytic leukemia (CLL) receiving venetoclax as a monotherapy or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib as prescribed at the discretion of the physician and in accordance with local clinical practice and label.
Eligibility Criteria
Inclusion Criteria: \- Participant with chronic lymphocytic leukemia (CLL) who start venetoclax therapy can be included in the study if treated as specified in the local label for any specific line of treatment. Exclusion Criteria: \- None
Contact & Investigator
ABBVIE INC.
STUDY DIRECTOR
AbbVie
Frequently Asked Questions
Who can join the NCT03342144 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Lymphocytic Leukemia (CLL). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03342144 currently recruiting?
Yes, NCT03342144 is actively recruiting participants. Contact the research team at johannes.huelsenbeck@abbvie.com for enrollment information.
Where is the NCT03342144 trial being conducted?
This trial is being conducted at Sankt Pölten, Austria, Graz, Austria, Salzburg, Austria, Vienna, Austria and 11 additional locations.
Who is sponsoring the NCT03342144 clinical trial?
NCT03342144 is sponsored by AbbVie. The principal investigator is ABBVIE INC. at AbbVie. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.